WallStreetZen

NYSE: NVO
Novo Nordisk A S Stock Forecast, Predictions & Price Target

Analyst price target for NVO

Based on 0 analysts offering 12 month price targets for Novo Nordisk A S.
Insufficient data to display

Should I buy or sell NVO stock?

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

NVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Emmanuel Papadakis
Deutsche Bank
Strong BuyInitiates Coverage OnN/AN/A2021-01-15

1 of 1

Forecast return on equity

Is NVO forecast to generate an efficient return?
Company
88.35%
Industry
-6.73%
Market
32,279.67%
NVO's Return on Equity is forecast to be high in 3 years (88.35%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NVO forecast to generate an efficient return on assets?
Company
38.61%
Industry
19.13%
Market
11,627.87%
NVO is forecast to generate higher Return on Assets (38.61%) than the US Biotechnology industry average (19.13%)
Forecast

NVO earnings per share forecast

What is NVO's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$3.08+4.09%
Avg 2 year Forecast
$3.35+13.15%
Avg 3 year Forecast
$3.65+23.35%
NVO's earnings are forecast to grow at a rate of 7.17% per year, which is not exceptional
Forecast

NVO revenue forecast

What is NVO's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$21.2B+2%
Avg 2 year Forecast
$22.7B+9.16%
Avg 3 year Forecast
$24.4B+17.27%
NVO's revenue is forecast to grow at a rate of 5.46% per year, which is not exceptional
Forecast

NVO earnings growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
7.17%
Industry
6.68%
Market
23.11%
NVO's earnings are forecast to grow faster (7.17% per year) than the US Biotechnology industry average (6.68%)
Forecast
NVO's earnings are forecast to grow slower (7.17% per year) than the US market average (23.11%)
Forecast
NVO's earnings are forecast to grow faster (7.17% per year) than the risk-free savings rate (1.7%)
Forecast

NVO revenue growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
5.46%
Industry
60.57%
Market
15.04%
NVO's revenues are forecast to grow slower (5.46% per year) than the US Biotechnology industry average (60.57%)
Forecast
NVO's revenues are forecast to grow slower (5.46% per year) than the US market average (15.04%)
Forecast

Novo Nordisk A S Stock Forecast FAQ

Is Novo Nordisk A S Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 1 Wall Street analysts covering (NYSE: NVO) stock is to Strong Buy NVO stock.

Out of 1 analysts, 1 (100%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 0 (0%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 0 (0%) are recommending NVO as a Strong Sell.

What is NVO's earnings growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual earnings growth rate of 7.17% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.11%.

Novo Nordisk A S's earnings in 2021 is $6,907,868,852.On average, 4 Wall Street analysts forecast NVO's earnings for 2021 to be $7,262,332,000, with the lowest NVO earnings forecast at $7,191,595,000, and the highest NVO earnings forecast at $7,309,490,000. On average, 5 Wall Street analysts forecast NVO's earnings for 2022 to be $7,894,249,200, with the lowest NVO earnings forecast at $7,309,490,000, and the highest NVO earnings forecast at $8,299,808,000.

In 2023, NVO is forecast to generate $8,606,335,000 in earnings, with the lowest earnings forecast at $8,040,439,000 and the highest earnings forecast at $9,148,652,000.

What is NVO's revenue growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 5.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.04%.

Novo Nordisk A S's revenue in 2021 is $20,810,819,672.On average, 2 Wall Street analysts forecast NVO's revenue for 2021 to be $50,051,968,565,000, with the lowest NVO revenue forecast at $49,454,075,862,000, and the highest NVO revenue forecast at $50,649,861,268,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2022 to be $53,565,819,608,400, with the lowest NVO revenue forecast at $50,061,635,955,000, and the highest NVO revenue forecast at $56,234,358,786,000.

In 2023, NVO is forecast to generate $57,546,200,030,000 in revenue, with the lowest revenue forecast at $53,533,054,230,000 and the highest revenue forecast at $60,753,816,453,000.

What is NVO's forecast return on assets (ROA) for 2021-2024?

(NYSE: NVO) forecast ROA is 38.61%, which is higher than the forecast US Biotechnology industry average of 19.13%.

What is NVO's Price Target?

According to 0 Wall Street analysts that have issued a 1 year NVO price target, the average NVO price target is N/A, with the highest NVO stock price forecast at N/A and the lowest NVO stock price forecast at N/A.

On average, Wall Street analysts predict that Novo Nordisk A S's share price could stay at N/A by Jan 15, 2022. The average Novo Nordisk A S stock price prediction forecasts a potential downside of N/A from the current NVO share price of $70.12.

What is NVO's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's current Earnings Per Share (EPS) is $2.96. On average, analysts forecast that NVO's EPS will be $3.08 for 2021, with the lowest EPS forecast at $3.05, and the highest EPS forecast at $3.10. On average, analysts forecast that NVO's EPS will be $3.35 for 2022, with the lowest EPS forecast at $3.10, and the highest EPS forecast at $3.52. In 2023, NVO's EPS is forecast to hit $3.65 (min: $3.41, max: $3.88).

What is NVO's forecast return on equity (ROE) for 2021-2024?

(NYSE: NVO) forecast ROE is 88.35%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.